Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
Prices for new US drugs doubled in 4 years as focus on rare disease grows
FDA expands warnings of heart risks on COVID shots
*please scroll down for all the latest news *
Make it like cafepharma, but for different industries. Learn more about CompanyUnderground
Check open job listings in your area
Click here to stay updated on CP happenings
learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
Prices for new US drugs doubled in 4 years as focus on rare disease grows
FDA expands warnings of heart risks on COVID shots
*please scroll down for all the latest news *
Make it like cafepharma, but for different industries. Learn more about CompanyUnderground
Check open job listings in your area
Click here to stay updated on CP happenings
learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud